Information Journal Paper
APA:
Copy. (2020). Safety and efficacy of MD1003 (highdose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET NEUROLOGY, 19(12), 988-997. SID. https://sid.ir/paper/672432/en
Vancouver:
Copy. Safety and efficacy of MD1003 (highdose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET NEUROLOGY[Internet]. 2020;19(12):988-997. Available from: https://sid.ir/paper/672432/en
IEEE:
Copy, “Safety and efficacy of MD1003 (highdose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial,” LANCET NEUROLOGY, vol. 19, no. 12, pp. 988–997, 2020, [Online]. Available: https://sid.ir/paper/672432/en